| Literature DB >> 31569458 |
Fadia S Youssef1, Mohamed L Ashour2,3, Abdel Nasser B Singab4, Michael Wink5.
Abstract
Fungal marine microorganisms are a valuable source of bioactive natural products. Fungal secondary metabolites mainly comprise alkaloids, terpenoids, peptides, polyketides, steroids, and lactones. Proteins and peptides from marine fungi show minimal human toxicity and less adverse effects comparable to synthetic drugs. This review summarizes the chemistry and the biological activities of peptides that were isolated and structurally elucidated from marine fungi. Relevant fungal genera including Acremonium, Ascotricha, Aspergillus, Asteromyces, Ceratodictyon, Clonostachys, Emericella, Exserohilum, Microsporum, Metarrhizium, Penicillium, Scytalidium, Simplicillium, Stachylidium, Talaromyces, Trichoderma, as well as Zygosporium were extensively reviewed. About 131 peptides were reported from these 17 genera and their structures were unambiguously determined using 1D and 2D NMR (one and two dimensional nuclear magnetic resonance) techniques in addition to HRMS (high resolution mass spectrometry). Marfey and Mosher reactions were used to confirm the identity of these compounds. About 53% of the isolated peptides exhibited cytotoxic, antimicrobial, and antiviral activity, meanwhile, few of them showed antidiabetic, lipid lowering, and anti-inflammatory activity. However 47% of the isolated peptides showed no activity with respect to the examined biological activity and thus required further in depth biological assessment. In conclusion, when searching for bioactive natural products, it is worth exploring more peptides of fungal origin and assessing their biological activities.Entities:
Keywords: biological activity; chemistry; marine derived fungi; peptides
Mesh:
Substances:
Year: 2019 PMID: 31569458 PMCID: PMC6835287 DOI: 10.3390/md17100559
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1(A) Cordyheptapeptides isolated from Acremonium species. (B) Efrapeptins isolated from Acremonium species. (C) RHM family isolated from Acremonium species.
Figure 2Peptides isolated from Ascotricha species.
Figure 3(A) Peptides isolated from Aspergillus carneus, A. niger, A. sclerotiorum, and A. terreus. (B) Peptides isolated from A. terreus, A. unguis, and A. unilateralis. (C) Peptides isolated from A. versicolor and A. violaceofuscus. (D) Peptides isolated from miscellaneous Aspergillus species.
Figure 4Peptides isolated from Asteromyces, Ceratodictyon, Clonostachys, Emericella, Exserohilum, and Microsporum species.
Figure 5Peptides isolated from Metarrhizium and Penicillium species.
Figure 6Peptides isolated from Scytalidium, Simplicillium, and Stachylidium species.
Figure 7Peptides isolated from Talaromyces and Zygosporium species.
Bioactive peptides isolated from marine associated fungi, their sources, and biological activities.
| Compound |
| Biological Activity | Reference |
|---|---|---|---|
| Cordyheptapeptide C ( |
|
Cytotoxic activity versus MCF-7, SF-268 and NCI-H460 cancer cells | [ |
| Cordyheptapeptide E ( |
|
Cytotoxic activity versus MCF-7, SF-268 and NCI-H460 cancer cells | [ |
| Efrapeptin Eα ( |
|
Cytotoxic activity versus H125 cells | [ |
| Efrapeptin F ( |
|
Cytotoxic activity versus H125 cells | [ |
| Efrapeptin G ( |
|
Cytotoxic activity versus H125 and HCT-116 cells Antibacterial activity versus | [ |
| RHM1 ( |
|
Antibacterial activity versus | [ |
| Aspergillicins A–E ( |
|
Cytotoxic activity | [ |
| Cyclo-(L-Trp-L-Tyr) ( |
|
Cytotoxic activity versus HT-29 cancer cells | [ |
| Sclerotide A ( |
|
Antifungal activity versus | [ |
| Sclerotide B ( |
|
Antifungal activity versus Antibacterial activity versus Weak cytotoxic activity versus HL-60 cell ( IC50 > 50 µM) | [ |
| Similanamide ( |
|
Weak cytotoxic activity versus MCF-7, A373 and NCI-H460 cancer cells (GI50 > 0.15 µM) | [ |
| Terrelumamide A ( |
|
Improve insulin sensitivity | [ |
| Terrelumamide B ( |
|
Improve insulin sensitivity | [ |
| Compound ( |
|
Cytotoxic activity versus U937 and MOLT4 human cancer cell lines Antiviral activity versus influenza virus of H1N1 and H3N2 strains | [ |
| Psychrophilin E ( |
|
Cytotoxic activity versus HCT116 | [ |
| Psychrophilin G ( |
|
Lipid-lowering activity | [ |
| Aspersymmetide A ( |
|
Weak cytotoxic activity versus NCI-H292 as well as A431 cell lines ( IC50 > 10 µM) | [ |
| Cotteslosin A ( |
|
Weak cytotoxic activity versus human melanoma (MM418c5), prostate (DU145) and breast (T47D) cells ( EC50> 0.1 µM | [ |
| Diketopiperazine dimer ( |
|
Anti-inflammatory activity against IL-10 expression of the LPS-induced THP-1 cells | [ |
| Cyclic tetrapeptide ( |
|
Anti-inflammatory activity against IL-10 expression of the LPS-induced THP-1 cells | [ |
| Aspergillipeptid D ( |
|
Antiviral activity versus herpes simplex virus type 1 (HSV-1) and acyclovir resistant clinical isolates | [ |
| Aspergillipeptide E ( |
|
Antiviral activity versus herpes simplex virus type 1 (HSV-1) | [ |
| 14-Hydroxy-cyclopeptine ( |
|
Inhibition of nitric oxide production | [ |
| Lajollamide A ( |
|
Weak antimicrobial activity versus Bacillus subtilis and Staphylococcus epidermidis. (MIC > 50 µM) | [ |
| Dictyonamide A ( |
|
Inhibition on cyclin-dependent kinase 4 | [ |
| Clonostachysin A ( |
|
Inhibition of dinoflagellate | [ |
| Clonostachysin B ( |
|
Inhibition of dinoflagellate | [ |
| Unguisin A ( |
|
Antimicrobial activity versus MRSA (methicillin resistant | [ |
| Emericellamide B ( |
|
Antimicrobial activity versus MRSA (methicillin resistant | [ |
| Rostratins A–D ( |
|
Cytotoxic activity versus (HCT-116) the human colon carcinoma | [ |
| Microsporin A ( |
|
Inhibition of histone deacetylase Cytotoxic activity versus human colon adenocarcinoma (HCT-116) and the 60 cancer cell panel of the National Cancer Institute | [ |
| Microsporin B ( |
|
Inhibition of histone deacetylase Cytotoxic activity versus human colon adenocarcinoma (HCT-116) | [ |
| Compound ( |
|
Antibacterial activity versus | [ |
| Compounds ( |
|
Cytotoxic activity versus MCF-7 and HCT115 cell lines | [ |
| Penicimutide ( |
|
Cytotoxic activity versus HeLa cells | [ |
| Gliocladine C ( |
|
Cytotoxic activity versus HepG2 cells | [ |
|
|
Inhibition to the biofilm formation | [ | |
| Halovir A ( |
|
Antiviral activity versus herpes simplex viruses of both type 1 and type 2 and HSV-1 | [ |
| Halovirs B–E ( |
|
Antiviral activity versus herpes simplex viruses of both type 1 and type 2 | [ |
| Simplicilliumtide A ( |
|
Weak cytotoxic activity versus human leukemia HL-60 and K562 cell line | [ |
| Simplicilliumtide D ( |
|
Antifouling effect versus the larvae of | [ |
| Simplicilliumtides E ( |
|
Weak cytotoxic effect versus human leukemia HL-60 and K562 cell line ( IC50 > 100 µM) | [ |
| Simplicilliumtide J ( |
|
Antifungal activity versus Curvularia australiensis and Aspergillus versicolor Antiviral activity versus HSV-1 | [ |
| Endolide A ( |
|
Binding activity to the vasopressin receptor 1A | [ |
| Endolide B ( |
|
Binding to serotonin receptor 5HT2b | [ |
| Talaropeptide A ( |
|
Antibacterial activity versus | [ |
| Talaropeptide B ( |
|
Antibacterial activity versus | [ |
| Zygosporamide ( |
|
Cytotoxic activity versus NCI’s 60 cell line panel, CNS cancer cell line SF-268, renal cancer cell line RXF 393 | [ |
Figure 8Percentages of isolated peptides with respect to their biological activity represented by a pie chart.